Indomethacin: Can It Counteract Bradykinin Effects in COVID-19 Patients?
Myasar Alkotaji, Radhwan N Al-Zidan
Current Pharmacology Reports, doi:10.1007/s40495-021-00257-6
COVID-19 represents the biggest health challenge. Although the mortality rate of COVID-19 is low, the high numbers of infected people and those with post-COVID-19 symptoms represent a real problem for the health system. A high number of patients with COVID-19 or people recovered from COVID-19 suffer from a dry cough and/or myalgia. Interestingly, an imbalance in bradykinin was observed in COVID-19 patients, which might be due to the accumulation of bradykinin as a result of a reduction in the degradation of bradykinin. This finding inspired the idea of possible similitude between the dry cough that is induced by angiotensin-converting enzyme inhibitors and the COVID-19-induced dry cough. Both of these types of cough are mediated, at least partially, by bradykinin. They both manifested as a persistent dry cough that is not responded to traditional dry cough remedies. However, several drugs were previously investigated for the treatment of angiotensin-converting enzyme inhibitor-induced dry cough. Here, we hypothesized that such treatment might be useful in COVID-19-induced dry cough and other bradykinin-related symptoms such as generalized pain and myalgia. In this article, evidence was presented to support the use of indomethacin as a potential treatment of COVID-19-induced dry cough. The choice of indomethacin was based on its ability to suppress the cyclooxygenase enzyme while also lowering the level of the inflammatory mediator bradykinin. Furthermore, indomethacin has been shown to be effective in treating angiotensin-converting enzyme inhibitor-induced dry cough. Moreover, indomethacin is a long-established, low-cost, effective, and readily available medication.
Declarations Ethics Approval and Consent to Participate Not applicable. Consent for Publication Not applicable.
Conflict of Interest The authors declare that there is no conflict of interest.
References
Al-Shamlan, El-Hashim, Bradykinin sensitizes the cough reflex via a B 2 receptor dependent activation of TRPV1 and TRPA1 channels through metabolites of cyclooxygenase and 12-lipoxygenase, Respir Res
Alkotaji, Azithromycin and ambroxol as potential pharmacotherapy for SARS-CoV-2, Int J Antimicrob Agents
Amici, Frazia, Brunelli, Balsamo, Angelini et al., Inhibition of viral protein translation by indomethacin in vesicular stomatitis virus infection: role of eif2α kinase PKR, Cell Microbiol
Bahrami, Daryani, Haghpanah, Moayyeri, Moghadam et al., Effects of indomethacin on viral replication markers in asymptomatic carriers of hepatitis B: a randomized, placebo-controlled trial, Am J Gastroenterol
Barzegar, Rezaei, Forouzesh, Valizadeh, New hope for treatment of respiratory involvement following COVID-19 by bromhexine, J Nephropharmacol
Carfì, Bernabei, Landi, Persistent symptoms in patients after acute COVID-19, JAMA
Cascella, Rajnik, Cuomo, Dulebohn, Napoli, COVID-19
Cazzola, Matera, Liccardi, Prisco, Amato et al., Theophylline in the inhibition of angiotensin-converting enzyme inhibitor-induced cough, Respiration
Davido, Seang, Tubiana, De Truchis, Post-COVID-19 chronic symptoms: a postinfectious entity?, Clin Microbiol Infect
Day, Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists, BMJ
Dicpinigaitis, Angiotensin-converting enzyme inhibitorinduced cough: ACCP evidence-based clinical practice guidelines, Chest
Dong, Du, Gardner, An interactive web-based dashboard to track COVID-19 in real time, Lancet Infect Dis
Esba, Alqahtani, Thomas, Shamas, Alswaidan et al., Ibuprofen and NSAID use in COVID-19 infected patients is not associated with worse outcomes: a prospective cohort study, Infect Dis Ther
Fogari, Zoppi, Mugellini, Preti, Banderali et al., Effects of amlodipine, nifedipine GITS, and indomethacin on angiotensin-converting enzyme inhibitor-induced cough: a randomized, placebo-controlled, double-masked, crossover study, Curr Ther Res
Fox, Lalloo, Belvisi, Bernareggi, Chung et al., Bradykinin-evoked sensitization of airway sensory nerves: a mechanism for ACE-inhibitor cough, Nat Med
Garvin, Alvarez, Miller, Prates, Walker et al., A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm, Elife
Gavras, Bradykinin-mediated effects of ACE inhibition, Kidney Int
Ghahestani, Mahmoudi, Hajebrahimi, Khojine, Salehi-Pourmehr et al., Bradykinin as a probable aspect in SARS-Cov-2 scenarios: is bradykinin sneaking out of our sight? Iran, J Allergy Asthma Immunol
Guo, Fan, Chen, Wu, Zhang et al., Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19), JAMA Cardiol
Hargreaves, Benson, Inhaled sodium cromoglycate in angiotensin-converting enzyme inhibitor cough, Lancet
Hosoki, Chakraborty, Sur, Molecular mechanisms and epidemiology of COVID-19 from an allergist's perspective, J Allergy Clin Immunol
Huang, Wang, Li, Ren, Zhao et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet
Hörl, Nonsteroidal anti-inflammatory drugs and the kidney, Pharmaceuticals
Kapiciogğlu, Sari, Kaynar, Baki, Özoran, The effect of indomethacin on hepatitis B virus replication in chronic healthy carriers, Scand J Gastroenterol
Kreutz, Algharably, Ganten, Messerli, Reninangiotensin-system (RAS) und COVID-19-Zur Verordnung von RAS-Blockern, Dtsch Med Wochenschr
Lee, Park, Kim, Lee, Hong, Iron supplementation inhibits cough associated with ACE inhibitors, Hypertension
Lippi, South, Henry, Electrolyte imbalances in patients with severe coronavirus disease 2019 (COVID-19), Ann Clin Biochem
Little, Non-steroidal anti-inflammatory drugs and covid-19
Liu, Luo, Haase, Guo, Wang et al., The experiences of health-care providers during the COVID-19 crisis in China: a qualitative study, Lancet Glob Health
Liu, Wang, Luo, Qian, Wu et al., Experience of N-acetylcysteine airway management in the successful treatment of one case of critical condition with COVID-19: a case report, Medicine
Lucas, The pharmacology of indomethacin. Headache Head Face, Pain
Mcewan, Choudry, Fuller, The effect of sulindac on the abnormal cough reflex associated with dry cough, J Pharmacol Exp Ther
Moore, Carleton, Blin, Bosco-Levy, Droz, Does ibuprofen worsen COVID-19?
Mäkelä, Kuusi, Schröder, Inhibition of serum phospholipase-A2 in acute pancreatitis by pharmacological agents in vitro, Scand J Clin Lab Invest
Rn, Potential drug-drug and drug-disease interactions of selected experimental therapies used in treating COVID-19 patients, J Drug Deliv Ther
Roche, Roche, A hypothesized role for dysregulated bradykinin signaling in COVID-19 respiratory complications, FASEB J
Skogestad, Aronsen, Hypokalemia-induced arrhythmias and heart failure: new insights and implications for therapy, Front Physiol
Tenenbaum, Grossman, Shemesh, Fisman, Nosrati et al., Intermediate but not low doses of aspirin can suppress angiotensin-converting enzyme inhibitor-induced cough, Am J Hypertens
Tolouian, Vahed, Ghiyasvand, Tolouian, Ardalan, COVID-19 interactions with angiotensin-converting enzyme 2 (ACE2) and the kinin system; looking at a potential treatment, J Ren Inj Prev
Updated, WHO now doesn't recommend avoiding ibuprofen for COVID-19 symptoms, ScienceAlert. Retrieved
Van De Veerdonk, Kouijzer, De Nooijer, Van Der Hoeven, Maas et al., Outcomes associated with use of a kinin B2 receptor antagonist among patients with COVID-19, JAMA Netw Open
Van De Veerdonk, Netea, Van Deuren, Der Meer, Mast et al., Kinins and cytokines in COVID-19: a comprehensive pathophysiological approach
Van De Veerdonk, Netea, Van Deuren, Van Der Meer, De Mast et al., Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome, Elife
Wang, Hu, Hu, Zhu, Liu et al., Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China, JAMA
Wu, Mcgoogan, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention, JAMA
Yılmaz, Angiotensin-converting enzyme inhibitors induce cough, Turk Thorac J
Zhang, Gao, Vio, Xiao, Wu et al., Bradykinin stimulates renal Na + and K + excretion by inhibiting the K + channel (Kir4.1) in the distal convoluted tubule, Hypertension
Zwaveling, Van Wijk, Karim, Pulmonary edema in COVID-19: explained by bradykinin?, J Allergy Clin Immunol
